Hepatocellular Carcinoma Incidence in Alcohol-Associated Cirrhosis: Systematic Review and Meta-analysis
- PMID: 35940513
- PMCID: PMC10792532
- DOI: 10.1016/j.cgh.2022.06.032
Hepatocellular Carcinoma Incidence in Alcohol-Associated Cirrhosis: Systematic Review and Meta-analysis
Abstract
Background & aims: Alcohol is one of the leading causes of hepatocellular carcinoma (HCC). However, pooled estimates of HCC incidence in alcohol-associated cirrhosis have not been evaluated systematically. We performed a pooled analysis of time-to-event data to provide robust estimates for the incidence of HCC in alcohol-associated cirrhosis.
Methods: Medline, Embase, Cochrane Central Register, Scopus, and Web of Science were searched from inception to August 2021. Individual patient data were reconstructed from published Kaplan-Meier curves, and a pooled analysis of cumulative HCC incidence was performed using a random-effects model.
Results: We screened 5022 articles and included 18 studies (148,333 patients). In the pooled analysis, the cumulative incidence of HCC in alcohol-associated cirrhosis at 1, 5, and 10 years among studies that accounted for the competing risk of death without HCC was 1%, 3%, and 9%, respectively. A secondary analysis by traditional meta-analysis determined that the HCC incidence rate was higher in cohorts enrolled in a HCC surveillance program (18.6 vs 4.8 per 1000 person-years; P = .001) vs those who were not enrolled in a surveillance program. Meta-regression showed that diabetes, smoking, variceal bleeding, and hepatic decompensation were associated with a higher risk of HCC.
Conclusions: Our analysis determined that the 5- and 10- year cumulative risk of HCC in alcohol-associated cirrhosis was 3% and 9%, respectively, with a higher incidence in cohorts that were enrolled in a HCC surveillance program. These data should be validated further in large prospective studies, and may have important implications for HCC screening and surveillance among patients with alcohol-associated cirrhosis.
Keywords: Alcohol; Cirrhosis; Hepatocellular Carcinoma; Incidence.
Copyright © 2023 AGA Institute. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
These authors disclose the following: Daniel Q. Huang has received funding support from the Singapore Ministry of Health’s National Medical Research Council under its National Medical Research Council (NMRC) Research Training Fellowship (MOH-000595-01).
Figures


Similar articles
-
Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis.Health Technol Assess. 2007 Sep;11(34):1-206. doi: 10.3310/hta11340. Health Technol Assess. 2007. PMID: 17767898
-
Incidence of Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-analysis, and Meta-regression.Clin Gastroenterol Hepatol. 2022 Feb;20(2):283-292.e10. doi: 10.1016/j.cgh.2021.05.002. Epub 2021 May 28. Clin Gastroenterol Hepatol. 2022. PMID: 33965578
-
The risk of end stage liver disease and hepatocellular carcinoma among persons infected with hepatitis C virus: publication bias?Am J Gastroenterol. 2003 Nov;98(11):2535-42. doi: 10.1111/j.1572-0241.2003.07678.x. Am J Gastroenterol. 2003. PMID: 14638360
-
Fibrosis Stage-specific Incidence of Hepatocellular Cancer After Hepatitis C Cure With Direct-acting Antivirals: A Systematic Review and Meta-analysis.Clin Gastroenterol Hepatol. 2023 Jul;21(7):1723-1738.e5. doi: 10.1016/j.cgh.2022.04.013. Epub 2022 May 5. Clin Gastroenterol Hepatol. 2023. PMID: 35525392 Free PMC article.
-
Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: A systematic review and meta-analysis.Eur J Cancer. 2022 Sep;173:250-262. doi: 10.1016/j.ejca.2022.06.051. Epub 2022 Aug 6. Eur J Cancer. 2022. PMID: 35944373
Cited by
-
The effects of moderate alcohol consumption on non-alcoholic fatty liver disease.Clin Mol Hepatol. 2023 Feb;29(Suppl):S261-S267. doi: 10.3350/cmh.2022.0393. Epub 2022 Dec 22. Clin Mol Hepatol. 2023. PMID: 36545707 Free PMC article. Review.
-
Alcohol and Hepatocellular Carcinoma.Clin Liver Dis. 2024 Nov;28(4):633-646. doi: 10.1016/j.cld.2024.06.007. Epub 2024 Jul 23. Clin Liver Dis. 2024. PMID: 39362712 Review.
-
Role of hepatotropic viruses in promoting hepatocellular carcinoma-current knowledge and recent advances.Med Oncol. 2025 Mar 17;42(4):111. doi: 10.1007/s12032-025-02674-9. Med Oncol. 2025. PMID: 40095313 Review.
-
Noval ceRNA axis-mediated high expression of TOP2A correlates with poor prognosis and tumor immune infiltration of hepatocellular carcinoma.Transl Cancer Res. 2023 Dec 31;12(12):3486-3502. doi: 10.21037/tcr-23-755. Epub 2023 Dec 26. Transl Cancer Res. 2023. PMID: 38193002 Free PMC article.
-
ACG Clinical Guideline: Alcohol-Associated Liver Disease.Am J Gastroenterol. 2024 Jan 1;119(1):30-54. doi: 10.14309/ajg.0000000000002572. Epub 2023 Sep 1. Am J Gastroenterol. 2024. PMID: 38174913 Free PMC article.
References
-
- Singal AK, Mathurin P. Diagnosis and treatment of alcohol-associated liver disease: a review. JAMA 2021;326:165–176. - PubMed
-
- Crabb DW, Im GY, Szabo G, et al. Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2020;71:306–333. - PubMed
-
- Seitz HK, Bataller R, Cortez-Pinto H, et al. Alcoholic liver disease. Nat Rev Dis Primers 2018;4:16. - PubMed
-
- European Association for the Study of the Liver. EASL clinical practice guidelines: management of alcohol-related liver disease. J Hepatol 2018;69:154–181. - PubMed